CRH (CRH) H2 2016 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2016 earnings summary
19 Nov, 2026Executive summary
2016 delivered reported sales growth of 15% and EBITDA growth of 41%, with organic growth, acquisition contributions, margin gains, cash generation and debt reduction supporting performance.
Pro forma EBITDA growth was ~10% for the year; organic operating leverage reached 35%, above historical norms.
Improved margins and returns across regions were driven by portfolio reshaping and commercial and operational initiatives, alongside recovering markets in the Americas.
Financial highlights
Sales exceeded €27bn, up 15% YoY; EBITDA exceeded €3.1bn, up 41% YoY.
Organic sales increased €684m and organic EBITDA increased €239m; organic operating leverage was 35%.
Operating cash generation was €2.3bn, with EBITDA-to-cash conversion of 75%.
Currency was a €70m EBITDA headwind, including €50m from sterling.
Outlook and guidance
2017 outlook: continued progress in Europe, Americas volume and pricing growth broadly in line with 2016, and further improvement in Asia.
Long-term operating leverage guidance remains 15%–20%; 2017 is expected to face a tough H1 comparison after strong H1 2016 pro forma growth of 20%.
Expected 2017 effective tax rate is 27%–28%; interest expense was expected to remain relatively stable.
CapEx guidance was ~100% of depreciation on average, with planned Philippines capacity investment likely to take spending above that level over the next 2–3 years.
Progressive dividend policy; per-share dividend growth is expected to lag EPS growth while cover is rebuilt toward ~3x over the medium term from just over 2x.
Latest events from CRH
- Strong organic profit growth and cash generation cut year-end net debt below 3x EBITDA.CRH
H2 2015 - €3.3bn EBITDA, stronger margins and returns, and major acquisitions positioned for further growth.CRH
H2 2017 - U.S. momentum and cost actions supported 2013 progress as net debt fell EUR 519m.CRH
H2 2012 - H2 momentum improved as portfolio actions and disciplined investment set up a moderate 2014 recovery.CRH
H2 2013 - EBITDA rose 11% in 2014; 2015 priorities were growth, integration and debt reduction.CRH
H2 2014 - Sales rose 5% and EBITDA reached €1.66bn as margins proved resilient.CRH
H2 2011 - Cash discipline and cost savings steadied results as markets began to stabilize.CRH
H2 2010 - Q3 EBITDA held near prior year; FY26 guidance is $7.8B–$8.0B amid cost and residential headwinds.CRH
Q3 2026 - Q2 2026 saw strong growth, margin gains, and the Arcosa deal, supporting a positive outlook.CRH
Q2 2026